>Merck Molnupiravir, a covid-19 antiviral drug bought by the UK government in the amount of 2.23 million doses, is no better than placebo at lowering the risks of death and hospital admission, a pivotal UK trial has found.
>The Panoramic study, sponsored by the University of Oxford, found that 0.8% of patients in the molnupiravir group (103 of 12 516) and 0.8% in the usual care group (96 of 12 484) were admitted to hospital or died in the first 28 days (adjusted odds ratio 1.061 (95% bayesian credible interval 0.80 to 1.40)).
TLDR you have better survival odds with placebo than with this Merck drug
>The Panoramic study, sponsored by the University of Oxford, found that 0.8% of patients in the molnupiravir group (103 of 12 516) and 0.8% in the usual care group (96 of 12 484) were admitted to hospital or died in the first 28 days (adjusted odds ratio 1.061 (95% bayesian credible interval 0.80 to 1.40)).
TLDR you have better survival odds with placebo than with this Merck drug